Compare Hormel Foods Corp (HRL) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Repligen Corporation Common Stock — how do they compare? Hormel Foods Corp trades at $20.06 (market cap $10.90B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Hormel Foods Corp and Repligen Corporation Common Stock are close in size by market cap, and Hormel Foods Corp pays a 5.91% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hormel Foods Corp for 99 Days and Repligen Corporation Common Stock for 0 Days on average.
| HRL | RGEN | |
|---|---|---|
Market Cap | $10.90B | $11.31B |
Volume | 5,843,624 | 1,216,919 |
Sector | Consumer Staples | Health |
52-Week High | $26.50 | $194.57 |
52-Week Low | $19.19 | $102.87 |
Typical Hold Time | 99 Days | 0 Days |
Enterprise Value | $12.89B | $11.20B |
Dividend Yield | 5.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $19.21, down 0.47% with a bearish technical outlook. The stock shows mixed fundamentals with declining net margins (2.82% in 2026) but consistent earnings beats and a $1.06B Brakebush acquisition to expand foodservice presence. Valuation metrics include a P/E of 30.98 and P/S of 0.87, while analyst consensus is cautious with 20% buy ratings.
Investment outlook balances dividend stability (60-year growth streak) against margin pressures and acquisition integration risks. The consensus price target of $25 offers 30% upside, but weak technicals and shrinking dividend raises warrant caution. Key catalysts include Brakebush synergies and foodservice growth execution.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
